Analyst Price Target is $20.00
▲ +241.30% Upside Potential
This price target is based on 2 analysts offering 12 month price targets for Genenta Science in the last 3 months. The average price target is $20.00, with a high forecast of $25.00 and a low forecast of $15.00. The average price target represents a 241.30% upside from the last price of $5.86.
Current Consensus is
The current consensus among 2 investment analysts is to buy stock in Genenta Science.
Genenta Science S.p.A., a clinical-stage biotechnology company, engages in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors in Italy. The company's lead product candidate is Temferon, which is in Phase 1/2a clinical trials for use in the treatment of glioblastoma multiforme in patients with unmethylated MGMT gene promoter. It is also developing Temferon for use in the treatment of other solid tumor indications, locally advanced hepatocellular carcinoma, and intra-hepatic cholangiocarcinoma. The company was incorporated in 2014 and is headquartered in Milan, Italy.